Conference item icon

Conference item

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1093/annonc/mdx440.051

Authors


Expand authors...
Celgene Corporation More from this funder
Publisher:
Oxford University Press Publisher's website
Volume:
28
Issue:
suppl_5
Pages:
635-636
Publication date:
2017-09-18
Acceptance date:
2017-07-27
DOI:
ISSN:
0923-7534 and 1569-8041
Pubs id:
pubs:738403
URN:
uri:a956854d-1faa-47bf-aa60-bcc314b711d6
UUID:
uuid:a956854d-1faa-47bf-aa60-bcc314b711d6
Local pid:
pubs:738403

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP